Slide 1: Omnicell Investor Relations
os) Omnicell Investor Relations February 28, 2023
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains “forward-looking statements" within the meaning of federal securities laws. These forward-looking statements include statements with respect to 2023 guidance, strategic and growth opportunities, other expectations and other nor-historical informa
Slide 3: Our Mission
Our Mission Be the clinician’s most trusted partner for medication management. We are dedicated to continuously deliver innovative technology that helps our customers improve patient care, for everyone. Our Vision Deliver the most compelling automation and services that accelerate pharmacy perfectio
Slide 4: Our Strategy
Our Strategy Fundamentally transform the pharmacy care delivery model by delivering a set of services that touch the entire continuum of care, built on a single cloud platform. = a Point Central of Care Pharmacy INPATIENT Cu Specialty Retail Pharmacy OUTPATIENT Home
Slide 5: Omnicell: Compelling Growth Opportunities
Omnicell: Compelling Growth Opportunities Category creator Leading strategic partner to Resilient, long-term revenue Demonstrated track record of transforming the pharmacy health systems in large and growth accelerated by strong growth built on a platform of care delivery model growing market segmen
Slide 6: The Autonomous Pharmacy Framework — an Industry Vision
The Autonomous Pharmacy Framework — an Industry Vision ed Highly Autonomay Level 2 © 2023 Omnicell, Inc. 6
Slide 7: Our Comprehensive Solutions Fundamentally Deliver Better Healthcare
Our Comprehensive Solutions Fundamentally Deliver Better Healthcare Value Central Pharmacy Dispensing Service IV Compounding EZ Specialty Service ee Q~ Pharmacy Services Te Inventory Optimization Service Point of ro) Omnicell <5 EnlivenHealth Care Connected Intelligent Infrastructure Inpatient Outpa
Slide 8: Leader in Large and Growing Segments
Leader in Large and Growing Segments Omnicell is growing its leadership position across a potential $90 Billion+ TAM Estimated TAM Opportunity! $22 Billion Retail $90 Billion+ TOTAL TAM $19 Billion Point of Care $19 Billion Specialty Pharmacy Services $32 Billion Central Pharmacy
Slide 9: Deep Customer Relationships & Robust Backlog
3 More than 150 of the top 300 U.S. health systems! in long-term Deep Customer sole-source agreements Relationships & + Over 50,000 retail pharmacies and 75% of U.S. pharmacy patients Robust Backlog interact with Omnicell solutions Robust backlog of $1.215 Billion as of 12/31/2022 Customers increasi
Slide 10: Advanced Services: Accelerating Recurring Revenue Growth
Advanced Services Accelerating Recurring Revenue Growth Advanced Services (% of Total Revenue) Targeting 18% of total revenue for 2023 18% 14% 10% i 2020 2021 2022 2023E NOTE: Includes Central Pharmacy Dispensing Service (service portion), IV Compounding Service (service portion), EnlivenHealth solu
Slide 11: Advanced Services Business Model — Customer Example
Advanced Services Business Model — Customer Example Tech-Enabled Services Model (IVCS and CPDS) YEAR 1 YEAR 2 YEAR 3 YEAR 4-7 Product Revenue End of year 7 R Cash rn Cash Cash re fecurrin ceivet eceiv rece celvex hones Received scevved Received Received Net sales type lease ‘coe : Ss mm a hf Revenue
Slide 12: Strong Balance Sheet
4) Strong Balance Sheet $2.211M Free cash flow projected to grow slower than EBITDA as Omnicell reinvests in the transformation to $330M Advanced Services $32M $1;130M $1,016M $554M Cash and Cash Equivalents Total Assets Total Equity Liquidity and capital 19x structure support growth strategy Total
Slide 13: Backlog ($Million)
Backlog! ($Million) By type: As of December 31, 2022 As of December 31, 2021 Product Backlog $797 $977 Advanced Services Backlog* $418 $277 Total Backlog $1,215 $1,254 Short-Term Product Backlog $503 $745 Long-Term Product Backlog $294 $232 Short-Term Advanced Services Backlog? $49 $37 Long-Term Adv
Slide 14: Total Year Revenue Composition
Total Year Revenue Composition
Slide 15: 2022 Financial Snapshot
2022 Financial Snapshot 4Q-2022 YoY Change (%) TY-2022 YoY Change (%) Non-GAAP Results Total Revenues $298 Million -4% $1,297 Million +14% Gross Margin % 45.3% -450bps 478% -300bps Operating Expenses $124 Million +7% $480 Million +23% EBITDA $26 Million -50% $193 Million -16% Diluted Earnings Per Sh
Slide 16: 2023 Financial Guidance
2023 Financia Guidance Bookings! Total Revenues Product Revenues Service Revenues Not Provided $273-$283 Million $179-$184 Million $94-$99 Million $1.000-$1.100 Billion $1.150-$1.190 Billion $740-$760 Million $410-$430 Million Technical Services Revenues Advanced Services Revenues Not Provided Not P
Slide 17: A Better Way: Our ESG Strategy
A Better Way: Our Environmental, Social and Governance (ESG) Strategy @ Environment J Innovating for Energy Efficiency Actively contribute to realize 1.5° Celsius future by 2030 Innovation Accelerating for Perfection Design, and deliver, our products to minimize environmental footprint while maximiz
Slide 18: A Better Way: ESG Strategy
A Better Way: ESG Strategy Roadmap designed to create enduring long-term value for all of our stakeholders Significance of ESG Strategy to Omnicell ESG Program Recognitions & Awards 2022 Corporate Responsibility (CR), and the ESG strategy fostered within, is Fundamental Transparency Index” to our mi
Slide 19: A Better Way: Our ESG Strategy in Action
A Better Way: Our ESG Strategy in Action Environment + Decreased Scope 1 & 2 emissions in 2021 by 6% from 2019 + Conducted a Scope 1 & 2 climate risk assessment in 2022 * Goal to establish Scope 3 reduction targets by 2026 Governance * Recent Board refreshment with 2 new Directors added in last 3 ye
Slide 20: Omnicell is Positioned to Win
We Expect that Omnicell is Positioned to Win Based on Our Belief that: 1) © Y © Omnicell has the right Omnicell is positioned Omnicell is scaling With a track record of solutions and the right as the leading strategic Advanced Services to strong financial business model to partner to health capitali
Slide 21: Appendix
Appendix
Slide 22: Reconciliation of GAAP to Non-GAAP
Omnicell, Inc. Reconciliation of GAAP to Non-GAAP (Unaudited, in thousands, except per share data and percentage) Three Months Ended December 31, Year Ended December 31, 2022 2021 2022 2021 Reconciliation of GAAP revenues to non-GAAP revenues: GAAP revenues $ 297,674 $ 311,034 $ 1,295,947 $ 1,132,01
Slide 23: Reconciliation of GAAP to Non-GAAP
Omnicell, Inc. Reconciliation of GAAP to Non-GAAP (Unaudited, in thousands, except per share data and percentage) Three Months Ended December 31, Year Ended December 31, 2022 2021 2022 2021 Reconciliation of GAAP net income (loss) per share - diluted to non-GAAP net income per share - diluted: Share
Slide 24: Reconciliation of GAAP to Non-GAAP
Omnicell, Inc. Reconciliation of GAAP to Non-GAAP (Unaudited, in thousands, except per share data and percentage) Year Ended December 31, 2022 Year Ended December Convertible senior notes, net 566,571 31, 2022 Cash and cash equivalents (330,362) Revolver availability 500,000 Net debt 236,209 Cash an
Slide 25: Slide 25